11/5/2026

speaker
Operator
Conference Call Operator

Hello, everyone. Thank you for joining us and welcome to Doximity's second quarter 2026 earnings conference call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I'll now hand the conference over to Perry Gold. Perry, please go ahead.

speaker
Perry Gold
Investor Relations, Doximity

Thank you, operator. Hello and welcome to Doximity's fiscal 2027 second quarter earnings call. With me on the call today are Jeff Tangney, co-founder and CEO of Doximity, and Matt Sonefeldt, CFO. A complete disclosure of our results can be found in our press release issued earlier today, as well as in our related form 8K, along with a copy of our prepared remarks, all available on our website at investors.doximity.com. As a reminder, Today's call is being recorded and a replay will be available on our website. As part of our comments today, we will be making forward-looking statements. These statements are based on management's current views, expectations, and assumptions and are subject to various risks and uncertainties. Actual results may differ materially and we may disclaim any obligation to update any forward-looking statements or outlook. Please refer to the risk factors in our annual report on Form 10-K, any subsequent Form 10-Qs, and any other reports and filings with the SEC that may be filed from time to time, including our upcoming filing on Form 10-Q. Our forward-looking statements are based on assumptions that we believe to be reasonable as of today's date, November 5th, 2026. Of note, it is Doximity's policy to neither reiterate nor adjust the financial guidance provided on today's call unless it is also done through a public disclosure, such as a press release or through the filing of a Form 8-K. Today, we will discuss certain non-GAAP metrics that we believe aid in the understanding of our financial results. A historical reconciliation to comparable gap metrics can be found in today's earnings release. Finally, during the call, we may offer incremental metrics to provide greater insights into the dynamics of our business. These details may be one time in nature, and we may or may not provide updates on those metrics in the future. I would now like to turn the call over to our CEO and co-founder, Jeff Tangney. Jeff?

speaker
Jeff Tangney
Co-Founder and Chief Executive Officer, Doximity

Thanks, Perry. And thanks, everyone, for joining our second quarter earnings call. Today, I'll cover three things, our financials, AI accuracy, and engagement. First, our financials. Thank you very much. Now to AI accuracy. It's by far the number one concern doctors have about AI. AI deals in probabilities. Patient care demands precision. All of us have had the experience of hitting refresh on an AI answer and getting a different response. Thankfully, accuracy is where we continue to lead the way. For starters, we launched DoseCheck, a deterministic verifier for medication safety. In a study of over a quarter million AI drug dose queries across all major models, we found a 2.3% error rate. What's more, 40% of these errors are serious or even lethal. So from a million AI drug queries, 9,000 patients could get hurt. That's too many. Our dose check catches these errors using our built-in drug data set. It's painstaking work, and we're proud to do it. Second, we're excited to add UpToDate to our AI answers. Every clinical AI model has read the National Library of Medicine, which has all of the journals and guidelines, but Wolters Kluwer's UpToDate stands alone as the proprietary gold standard reference for point of care. Their 7,600 physician authors provide unique advice about what to do when there isn't an RCT or randomized controlled trial to answer the questions. We think this real-world medical layer is really important. And now, it's one tap away inside of Doximity. Independent tests keep confirming our lead in accuracy and safety. In September, we joined other vertical AI leaders like Harvey & Law and Sierra & Customer Service to create industry-specific benchmarks. When AI provider Fireworks graded the results, Doximity ranked first among 16 leading models, echoing our Stanford No Harm study results in July. Physician input is critical to getting AI and medicine right. This quarter, we convened our Medical AI Summit, 150 physicians, chiefs and chairs from our nation's best hospitals, joined by two former U.S. Surgeons General, Dr. Vivek Murthy and Dr. Regina Benjamin, to work through how we build clinical AI responsibly together. As a physician's first company, this unique semiannual event is our North Star and guides our roadmap. Finally, our engagement and client growth. Quarterly active workflow prescribers, which includes our AI users, grew 34% year on year to record highs, accelerating from last quarter. So for the first time, approximately half of all of the 1.8 million U.S. prescribers used us last quarter as part of their workflow. Our health system client footprint continued to grow as well, up over 190 on our AI suite from 165 last quarter, including 10 of the nation's top 20 hospitals. New York Presbyterian now provides access to Doximity AI directly from its EHR, giving New York Presbyterian, Columbia, and Weill Cornell Medicine clinicians convenient access to AI-powered tools and the latest medical research within their existing workflows. Over the past five years working with New York Presbyterian, we've seen firsthand why they're consistently ranked among the nation's best hospitals, and we're excited to grow our AI tool set with them. UCSD Health, the number one ranked hospital in San Diego, is another AI client and one of the first hospitals to adopt our new patient context feature. Directly from a patient's chart, our AI can read that patient's notes, labs, imaging, conditions, and coverage to give patient-specific answers and guideline-based treatment plans. It's the difference between a doctor asking a general medical question and asking about the patient in front of them. Our patient context feature is now available for thousands of doctors, and their writing prompts half as long, 12 words versus our 24-word average, because they no longer have to retype the chart details into a search bar. Our AI already has the labs, notes, and problem list, so it can find the pertinent clinical details deep in their records. To fit more workflows, we're opening API access to our clinical intelligence layer. If you're building time-saving tools for clinicians, we'd love to work with you. Just email us at bd.doximity.com. Last, on the pharma side, our AI search commercial offering has been well-received. 16 of the top 20 pharma companies have already purchased, with three more in contracting. and more than 100 clients attended our Pharma AI showcase last month, our biggest turnout ever. To sum up, with dose check and up-to-date, we lead on AI accuracy and trust. With 190 health system AI clients in patient context, we lead on distribution and integration. And with AI search now available to our Pharma clients, we're growing into a much larger market. As always, I'd like to end by thanking my Doximity teammates who continue to work incredibly hard to care for those who care for us. With that, I'll hand it over to our CFO, Matt Sonefeldt, to walk us through our financials and guidance. Matt?

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation